Belgium's Agomab Therapeutics raises $200 million in US IPO
Agomab Therapeutics has raised $200 million in its U.S. initial public offering, the company said on Thursday, setting the stage for a Nasdaq debut by the biopharmaceutical firm.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments